Influenza

11 trials MedDRA PT
11 Registered trials
0 Recruiting
9 Unique sponsors
20 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
J Anti-infectives (ATC J) 7
Mechanism of action (INN-stem analysis)
Unknown / small molecule 19 substances
Antiviral 1 substance
Phase III: 4 Phase II: 1 Phase IV: 2 Phase I: 2 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 11 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 11 trials

Phase III

4 trials
  • F. Hoffmann-La Roche AG Commercial
    BALOXAVIR MARBOXIL
    2023-504672-22-00 3 countries 2023 n=310
    Ended
  • Moderna Inc. Commercial
    B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022); CX-039776, CX-044933, CX-037231
    2024-516240-26-00 5 countries 2024 n=15,490
    Ended
  • Seqirus UK Limited Commercial
    B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022); B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022); INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED; INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022)
    2022-503004-24-00 10 countries 2023 n=27,275
    Ended
  • Seqirus UK Limited Commercial
    A/(H3N2)-LIKE VIRUS ANTIGEN, B (YAMAGATA LINEAGE)-LIKE VIRUS ANTIGEN, B (VICTORIA LINEAGE)-LIKE VIRUS ANTIGEN, A/H1N1 INFLUENZA VACCINE
    2023-503763-42-00 3 countries 2023 n=2,100
    Ended

Phase II

1 trial
  • OSIVAX Belgique Commercial
    INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES
    2024-516267-83-00 1 country 2024 n=117
    Ended

Phase IV

2 trials
  • Finnish Institute For Health And Welfare Academic
    IMP not specified
    2024-515372-12-00 1 country n=1,500
    Ended
  • Gentofte Hospital Academic
    B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224); B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED
    2022-500657-17-00 1 country 2022 n=339,700
    Ended

Phase I

2 trials
  • Sumitomo Pharma Co. Ltd. Commercial
    IMP not specified
    2023-504378-39-00 1 country 2024 n=144
    Ended
  • LiteVax B.V. Academic
    B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021; INFLUENZA QUADRIVALENT VACCINE (RDNA)
    2022-500681-98-00 1 country 2022 n=60
    Ended

Phase I (Other)

1 trial
  • LiteVax B.V. Academic
    IMP not specified
    2023-508230-33-00 1 country 2024 n=70
    Ended

Phase I (First in Human)

1 trial
  • GlaxoSmithKline Biologicals Commercial
    B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227); B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238); B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED; GSKVX000000034792; GSKVX000000034792, GSKVX000000034794, GSKVX000000034795, GSKVX000000034796, GSKVX000000034797, GSKVX000000034798, GSKVX000000039711, GSKVX000000040033; GSKVX000000034792, GSKVX000000034794, GSKVX000000034795, GSKVX000000040033; GSKVX000000034794, GSKVX000000034795, GSKVX000000034797, GSKVX000000034798, GSKVX000000039711, GSKVX000000040033, GSKVX000000048110, GSKVX000000048111
    2022-502308-66-00 1 country 2023 n=438
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seqirus UK Limited Commercial 2 Phase III 0
LiteVax B.V. Academic 2 Phase I, Phase I (Other) 0
Sumitomo Pharma Co. Ltd. Commercial 1 Phase I 0
OSIVAX Belgique Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Moderna Inc. Commercial 1 Phase III 0
GlaxoSmithKline Biologicals Commercial 1 Phase I (First in Human) 0
Finnish Institute For Health And Welfare Academic 1 Phase IV 0
Gentofte Hospital Academic 1 Phase IV 0
New trials by year
2022
2
2023
4
2024
4
← All indication landscapes